Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 52, 5291-5298, October 1, 1992]
© 1992 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coles, C.
Right arrow Articles by Prosser, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coles, C.
Right arrow Articles by Prosser, J.

p53 Mutations in Breast Cancer

Christopher Coles1, Alison Condie, Udi Chetty, C. Michael Steel, H. John Evans and Jane Prosser2

MRC Human Genetics Unit, Western General Hospital, Edinburgh EH4 2XU [C. C., A. C., C. M. S., H. J. E., J. P.], and Department of Surgery, Royal Infirmary, Edinburgh EH3 9YU [U. C.], Scotland

We have identified and analyzed 41 mutations in p53 in sporadic breast tumors from 136 unselected breast cancer patients and estimate that approximately 40% of such tumors contain p53 mutations. The frequency of G-T transversions and the incidence of guanosine mutations in the nontranscribed strand of the p53 gene were found to be higher than expected, and we suggest, therefore, that exogenous carcinogens have an etiological role in sporadic breast cancers. Mutations were recorded in 44 codons of the p53 gene, with no obvious mutational hot-spots, although mutations at codons 175, 194, 273, and 280 accounted for 25% of the changes. One germ-line mutation was found in 136 patients and so we conclude that constitutional mutation of p53 may be an uncommon etiological factor in breast cancer.

1 Supported by the British Breast Cancer Research Trust.

2 To whom requests for reprints should be addressed.

Received 4/ 2/92. Accepted 7/17/92.




This article has been cited by other articles:


Home page
Cancer Res.Home page
S. W.P. Wijnhoven, E. Zwart, E. N. Speksnijder, R. B. Beems, K. P. Olive, D. A. Tuveson, J. Jonkers, M. M. Schaap, J. van den Berg, T. Jacks, et al.
Mice Expressing a Mammary Gland-Specific R270H Mutation in the p53 Tumor Suppressor Gene Mimic Human Breast Cancer Development
Cancer Res., September 15, 2005; 65(18): 8166 - 8173.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
E. M. Johansson, M. Kannius-Janson, A. Gritli-Linde, G. Bjursell, and J. Nilsson
Nuclear Factor 1-C2 Is Regulated by Prolactin and Shows a Distinct Expression Pattern in the Mouse Mammary Epithelial Cells during Development
Mol. Endocrinol., April 1, 2005; 19(4): 992 - 1003.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
V. Meniel, T. Hay, A. Douglas-Jones, O. J. Sansom, and A. R. Clarke
Mutations in Apc and p53 Synergize to Promote Mammary Neoplasia
Cancer Res., January 15, 2005; 65(2): 410 - 416.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. C. Blackburn, S. C. McLary, R. Naeem, J. Luszcz, D. W. Stockton, L. A. Donehower, M. Mohammed, J. B. Mailhes, T. Soferr, S. P. Naber, et al.
Loss of Heterozygosity Occurs via Mitotic Recombination in Trp53+/- Mice and Associates with Mammary Tumor Susceptibility of the BALB/c Strain
Cancer Res., August 1, 2004; 64(15): 5140 - 5147.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
J. E. Green, K. V. Desai, Yumei Ye, C. Kavanaugh, A. Calvo, and J.-I. Huh
Application of Gene Expression Profiling for Validating Models of Human Breast Cancer
Toxicol Pathol, January 1, 2004; 32(1_suppl): 84 - 89.
[Abstract] [PDF]


Home page
Mol Cancer ResHome page
I. Hernandez, L. A. Maddison, Y. Wei, F. DeMayo, T. Petras, B. Li, J. R. Gingrich, J. M. Rosen, and N. M. Greenberg
Prostate-Specific Expression of p53R172L Differentially Regulates p21, Bax, and mdm2 to Inhibit Prostate Cancer Progression and Prolong Survival
Mol. Cancer Res., December 1, 2003; 1(14): 1036 - 1047.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
L. M. Minter, E. S. Dickinson, S. P. Naber, and D. J. Jerry
Epithelial cell cycling predicts p53 responsiveness to {gamma}-irradiation during post-natal mammary gland development
Development, March 8, 2003; 129(12): 2997 - 3008.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
M M de Jong, I M Nolte, G J te Meerman, W T A van der Graaf, J C Oosterwijk, J H Kleibeuker, M Schaapveld, and E G E de Vries
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility
J. Med. Genet., April 1, 2002; 39(4): 225 - 242.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. Sivaraman, O. M. Conneely, D. Medina, and B. W. O'Malley
p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis
PNAS, October 12, 2001; (2001) 221459098.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
K. Kurose, S. Hoshaw-Woodard, A. Adeyinka, S. Lemeshow, P. H. Watson, and C. Eng
Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions
Hum. Mol. Genet., September 1, 2001; 10(18): 1907 - 1913.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
K. E. Nichols, D. Malkin, J. E. Garber, J. F. Fraumeni Jr., and F. P. Li
Germ-line p53 Mutations Predispose to a Wide Spectrum of Early-onset Cancers
Cancer Epidemiol. Biomarkers Prev., February 1, 2001; 10(2): 83 - 87.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
C. Kuperwasser, J. Pinkas, G. D. Hurlbut, S. P. Naber, and D. J. Jerry
Cytoplasmic Sequestration and Functional Repression of p53 in the Mammary Epithelium Is Reversed by Hormonal Treatment
Cancer Res., May 1, 2000; 60(10): 2723 - 2729.
[Abstract] [Full Text]


Home page
Cell Growth Differ.Home page
V. L. Cressman, D. C. Backlund, E. M. Hicks, L. C. Gowen, V. Godfrey, and B. H. Koller
Mammary Tumor Formation in p53- and BRCA1-deficient Mice
Cell Growth Differ., January 1, 1999; 10(1): 1 - 10.
[Abstract] [Full Text]


Home page
CVIHome page
E. M. Rakowicz-Szulczynska, B. Jackson, A. M. Szulczynska, and M. Smith
Human Immunodeficiency Virus Type 1-Like DNA Sequences and Immunoreactive Viral Particles with Unique Association with Breast Cancer
Clin. Vaccine Immunol., September 1, 1998; 5(5): 645 - 653.
[Abstract] [Full Text]


Home page
INT J SURG PATHOLHome page
P. Robbins
p53 and Breast Cancer
International Journal of Surgical Pathology, October 1, 1996; 4(2): 93 - 110.
[Abstract] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. Sivaraman, O. M. Conneely, D. Medina, and B. W. O'Malley
p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis
PNAS, October 23, 2001; 98(22): 12379 - 12384.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1992 by the American Association for Cancer Research.